CEN BIOTECH, INC.: 10-Q filed 2020-11-06
What CEN BIOTECH, INC. reported in its quarterly report filed 2020-11-06 (fiscal Q3 2020): 28 published measures, 68 facts as tagged in accession 0001437749-20-022947.
This filing
- Form
- 10-Q (quarterly report)
- Filed
- 2020-11-06
- Fiscal period
- fiscal Q3 2020
- Accession
- 0001437749-20-022947 on SEC EDGAR
Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All CEN BIOTECH, INC. filings.
Reported measures
Total assets
Resources recognized on the balance sheet. Book assets are not the market value of the business.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 6,557,655 | USD | |
| At 2019-12-31 | 7,296,422 | USD |
Total liabilities
Recognized obligations at the reporting date. The definition and scope differ from interest-bearing debt.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 35,903,636 | USD | |
| At 2019-12-31 | 32,831,584 | USD |
Stockholders equity
The reported residual interest after liabilities. It is an accounting amount, not market capitalization.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | -29,345,981 | USD | |
| At 2019-12-31 | -25,535,162 | USD | |
| At 2019-09-30 | -24,594,257 | USD | |
| At 2018-12-31 | -21,261,393 | USD |
Cash and cash equivalents
Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 252 | USD | |
| At 2019-12-31 | 3,757 | USD |
Net income or loss
Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -1,926,176 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -4,886,169 | USD | 274 |
| 2019-07-01 to 2019-09-30 | -1,332,512 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -4,425,914 | USD | 273 |
Operating cash flow
Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | -399,306 | USD | 274 |
| 2019-01-01 to 2019-09-30 | -546,149 | USD | 273 |
Financing cash flow
Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 499,000 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 703,554 | USD | 273 |
Investing cash flow
Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | -103,199 | USD | 274 |
| 2019-01-01 to 2019-09-30 | -160,000 | USD | 273 |
Retained earnings or deficit
Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | -46,196,341 | USD | |
| At 2019-12-31 | -41,310,172 | USD |
Net property, plant and equipment
Carrying amount of property, plant and equipment after accumulated depreciation, depletion and amortization. It is not replacement cost or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 148,125 | USD |
Share-based compensation expense
Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | 196,650 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 589,950 | USD | 274 |
| 2019-07-01 to 2019-09-30 | 243,150 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 956,700 | USD | 273 |
Operating income or loss
Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -968,424 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,189,621 | USD | 274 |
| 2019-07-01 to 2019-09-30 | -517,126 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -1,918,967 | USD | 273 |
Current liabilities
Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 34,617,522 | USD | |
| At 2019-12-31 | 30,868,408 | USD |
Current accounts payable
Current amounts owed to suppliers for goods and services received. This is one component of current liabilities, not all accrued obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 211,294 | USD | |
| At 2019-12-31 | 181,266 | USD |
Net finite-lived intangible assets
Finite-lived intangible assets after amortization. This excludes goodwill and should not be combined with indefinite-lived intangible assets without checking scope.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 5,062,350 | USD | |
| At 2019-12-31 | 5,380,959 | USD |
Operating expenses
Recurring operating costs under this accounting concept, generally excluding production costs included in cost of sales. Check filing presentation before combining expense subtotals.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | 968,424 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 2,189,621 | USD | 274 |
| 2019-07-01 to 2019-09-30 | 517,126 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 1,918,967 | USD | 273 |
Common shares outstanding
Common shares outstanding at the reporting date. This point-in-time count differs from the weighted-average shares used for earnings per share and can exclude other share classes.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 27,512,363 | shares | |
| At 2019-12-31 | 26,953,363 | shares |
Additional paid-in capital
Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 16,850,360 | USD | |
| At 2019-12-31 | 15,775,010 | USD |
Operating lease right-of-use asset
Carrying amount of the right to use leased assets under operating leases. It reflects discounted remaining payments, not the value of the underlying property.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 229,284 | USD |
Operating lease liability
Present value of remaining operating lease payments. Discount-rate choices and lease terms affect the amount; it is not the sum of undiscounted future rent.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 154,504 | USD |
Accumulated depreciation on property, plant and equipment
Cumulative depreciation, depletion and amortization recorded against property, plant and equipment. It measures cost allocation to date, not physical wear or market value.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2019-12-31 | 35,706 | USD |
Net intangible assets excluding goodwill
Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 5,062,350 | USD | |
| At 2019-12-31 | 5,380,959 | USD |
Accrued current liabilities
Current obligations accrued for goods and services received but not yet invoiced or paid. This is one component of current liabilities, not all short-term obligations.
| Period | Value | Unit | Days |
|---|---|---|---|
| At 2020-09-30 | 609,823 | USD | |
| At 2019-12-31 | 574,723 | USD |
General and administrative expense
General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | 268,487 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 871,907 | USD | 274 |
| 2019-07-01 to 2019-09-30 | 223,519 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 823,731 | USD | 273 |
Depreciation expense
Depreciation recognized for the period under this concept. It is a noncash allocation of asset cost and may exclude amortization and depletion reported elsewhere.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | 1,532 | USD | 92 |
| 2020-01-01 to 2020-09-30 | 10,724 | USD | 274 |
| 2019-07-01 to 2019-09-30 | 4,596 | USD | 92 |
| 2019-01-01 to 2019-09-30 | 13,788 | USD | 273 |
Amortization of intangible assets
Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 318,609 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 318,609 | USD | 273 |
Nonoperating income or expense
Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-07-01 to 2020-09-30 | -957,752 | USD | 92 |
| 2020-01-01 to 2020-09-30 | -2,696,548 | USD | 274 |
| 2019-07-01 to 2019-09-30 | -815,386 | USD | 92 |
| 2019-01-01 to 2019-09-30 | -2,506,947 | USD | 273 |
Interest paid, net
Cash interest paid during the period, net of amounts capitalized where the filer reports it that way. It differs from interest expense recognized.
| Period | Value | Unit | Days |
|---|---|---|---|
| 2020-01-01 to 2020-09-30 | 41,527 | USD | 274 |
| 2019-01-01 to 2019-09-30 | 38,913 | USD | 273 |
Inspect the source
- Entity
- CEN BIOTECH, INC. / CIK 0001653821
- Captured
- SEC response SHA-256
097c84c6c785c728d94a8aab95d5185c6c0595b9a921b7610327e115a19292be
Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON
Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.
Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.
Use this in research
A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.
These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.
Research methodology · Execution and cost assumptions · Check backtest overfitting
Build with the open-source tools
Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.
- Get an API key and run your first validation
- Connect the MCP server to your coding assistant
- Inspect the ALPHAC engine on GitHub
- Read the MCP server source and integration examples
Read the published dataset with Python
import json
from urllib.request import urlopen
with urlopen("https://canlicapital.com/company-data/0001653821.json") as response:
record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
print(concept["tag"], next(iter(concept["observations"])))